Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): Targeting Vpr and its cellular partner, the glucocorticoid receptor (GR)

Antiviral Research

Volumn 72, Issue 3, 2006, Pages 224-232

  Schafer, Elizabeth A ^a   Venkatachari, Narasimhan J ^a   Ayyavoo, Velpandi ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiviral; Glucocorticoid receptor; HIV 1; Mifepristone; Vpr

Indexed keywords

GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; MIFEPRISTONE; VPR PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, VPR; HELA CELLS; HIV CORE PROTEIN P24; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MIFEPRISTONE; PROMOTER REGIONS (GENETICS); RECEPTORS, GLUCOCORTICOID; TRANS-ACTIVATION (GENETICS); VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33750686566     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.06.008     Document Type: Article

References (65)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., and Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59 (1986) 284-291
2. Agostini I., Navarro J.M., Rey F., Bouhamdan M., Spire B., Vigne R., and Sire J. The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB. J. Mol. Biol. 261 (1996) 599-606
3. Ayyavoo V., Mahboubi A., Mahalingam S., Ramalingam R., Kudchodkar S., Williams W.V., Green D.R., and Weiner D.B. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat. Med. 3 (1997) 1117-1123
4. Ayyavoo V., Muthumani K., Kudchodkar S., Zhang D., Ramanathan P., Dayes N.S., Kim J.J., Sin J.I., Montaner L.J., and Weiner D.B. HIV-1 viral protein R compromises cellular immune function in vivo. Int. Immunol. 14 (2002) 13-22
5. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Armaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5698-5703
6. Brogden R.N., Goa K.L., and Faulds D. Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 45 (1993) 309-384
7. Chariot P., Drogou I., de Lacroix-Szmania I., Eliezer-Vanerot M.C., Chazaud B., Lombes A., Schaeffer A., and Zafrani E.S. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J. Hepatol. 30 (1999) 156-160
8. Cohen E.A., Dehni G., Sodroski J.G., and Haseltine W.A. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J. Virol. 64 (1990) 3097-3099
9. Collman R.G., Perno C.F., Crowe S.M., Stevenson M., and Montaner L.J. HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J. Leukoc. Biol. 74 (2003) 631-634
10. Collman R., Hassan N.F., Walker R., Godfrey B., Cutilli J., Hastings J.C., Friedman H., Douglas S.D., and Nathanson N. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J. Exp. Med. 170 (1989) 1149-1163
11. Collman R., Balliet J.W., Gregory S.A., Friedman H., Kolson D.L., Nathanson N., and Srinivasan A. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66 (1992) 7517-7521
12. Connor R.I., Chen B.K., Choe S., and Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type 1 in mononuclear phagocytes. Virology 206 (1995) 935-944
13. d'Arminio Monforte A., Lepri A.C., Rezza G., Pezzotti P., Antinori A., Phillips A.N., Angarano G., Colangeli V., De Luca A., Ippolito G., Caggese L., Soscia F., Filice G., Gritti F., Narciso P., Tirelli U., and Moroni M. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 14 (2000) 499-507
14. Deloria-Knoll M., Chmiel J.S., Moorman A.C., Wood K.C., Holmberg S.D., Palella F.J., and the HIV Outpatient Study (HOPS) Investigators. Factors related to and consequences of adherence to antiretroviral therapy in an ambulatory HIV-infected patient cohort. AIDS Patient Care STDS 18 (2004) 721-727
15. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., Kappes J.C., Shaw G.M., and Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74 (2000) 8358-8367
16. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., and Moore J.P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4 (1998) 72-77
17. Feng W., Ribeiro R.C., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., Baxter J.D., Kushner P.J., and West B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280 (1998) 1747-1749
18. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., and Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (1997) 1295-1300
19. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., and Siliciano R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5 (1999) 512-517
20. Friis-Moller N., Weber R., Reiss P., Thiebaut R., Kirk O., d'Arminio Monforte A., Pradier C., Morfeldt L., Mateu S., Law M., El-Sadr W., De Wit S., Sabin C.A., Phillips A.N., Lundgren J.D., and DAD Study Group. Cardiovascular disease risk factors in HIV patients association with antiretroviral therapy. Results from the DAD study. AIDS 17 (2003) 1179-1193
21. Fukumori T., Akari H., Yoshida A., Fujita M., Koyama A.H., Kagawa S., and Adachi A. Regulation of cell cycle and apoptosis by human immunodeficiency virus type 1 Vpr. Microbes. Infect. 2 (2000) 1011-1017
22. Gartner S., Markovits P., Markovitz D.M., Kaplan M.H., Gallo R.C., and Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233 (1986) 215-219
23. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36 (1977) 59-74
24. Harris R.S., and Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4 (2004) 868-877
25. Hattori N., Michaels F., Fargnoli K., Marcon L., Gallo R.C., and Franchini G. The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 8080-8084
26. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., and Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69 (1995) 6705-6711
27. Heery D.M., Kalkhoven E., Hoare S., and Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 (1997) 733-736
28. Hrimech M., Yao X.J., Bachand F., Rougeau N., and Cohen E.A. Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J. Virol. 73 (1999) 4101-4109
29. Jeeninga R.E., Hoogenkamp M., Armand-Ugon M., de Baar M.D., Verhoef K., and Berkhout B. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol. 74 (2000) 3740-3751
30. Jowett J.B., Planelles V., Poon B., Shah N.P., Chen M.L., and Chen I.S. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2+ M phase of the cell cycle. J. Virol. 69 (1995) 6304-6313
31. Kauppi B., Jakob C., Färnegårdh M., Yang J., Ahola H., Alarcon M., Calles K., Engström O., Harlan J., Muchmore S., Ramqvist A.K., Thorell S., Öhman L., Greer J., Gustafsson J.A., Carlstedt-Duke J., and Carlquist M. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 278 (2003) 22748-22754
32. Kino T., Gragerov A., Kopp J.B., Stauber R.H., Pavlakis G.N., and Chrousos G.P. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J. Exp. Med. 189 (1999) 51-62
33. Klaver B., and Berkhout B. Comparison of 5′ and 3′ long terminal repeat promoter function in human immunodeficiency virus. J. Virol. 68 (1994) 3830-3840
34. Kutsch O., Benveniste E.N., Shaw G.M., and Levy D.N. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J. Virol. 76 (2002) 8776-8786
35. Lambotte O., Taoufik Y., de Goer M.G., Wallon C., Goujard C., and Delfraissy J.F. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 23 (2000) 114-119
36. Levy D.N., Refaeli Y., MacGregor R.R., and Weiner D.B. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 10873-10877
37. Levy D.N., Refaeli Y., and Weiner D.B. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J. Virol. 69 (1995) 1243-1252
38. Lucas G.M. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J. Antimicrob. Chem. 55 (2005) 413-416
39. Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., and Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47 (1986) 333-348
40. Majumder B., Janket M.L., Schafer E.A., Schaubert K., Huang X.L., Kan-Mitchell J., Rinaldo Jr. C.R., and Ayyavoo V. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape. J. Virol. 79 (2005) 7990-8003
41. Montessori V., Press N., Harris M., Akagi L., and Montaner J.S. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170 (2004) 229-238
42. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
43. Nakamura T., Suzuki H., Okamoto T., Kotani S., Atsuji Y., Tanaka T., and Ito Y. Recombinant Vpr (rVpr) causes augmentation of HIV-1 p24 Ag level in U1 cells through its ability to induce the secretion of TNF. Virus Res. 90 (2002) 263-268
44. Pandit S., Geissler W., Harris G., and Sitlani A. Allosteric effects of dexamethasone and RU486 on glucocorticoid receptor-DNA interactions. J. Biol. Chem. 277 (2002) 1538-1543
45. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., and Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72 (1998) 2855-2864
46. Pommier Y., Johnson A.A., and Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4 (2005) 236-248
47. Popov S., Rexach M., Zybarth G., Reiling N., Lee M.A., Ratner L., Lane C.M., Moore M.S., Blobel G., and Bukrinsky M. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J. 17 (1998) 909-917
48. Popovic M., Gartner S., Read-Connole E., Beaver B., and Reitz M. Cell tropism and expression of HIV-1 isolates in natural targets. In: Girard, and Valette (Eds). Retroviruses of Human A.I.D.S. and Related Animal Diseases, Colloque Des Cent Gardes. Marnes-La-Coquette, Paris, October 27-29, 1988 (1989) 21-27
49. Richman D.D. HIV chemotherapy. Nature 410 (2001) 995-1001
50. Rucker E., Grivel J.C., Munch J., Kirchhoff F., and Margolis L. Vpr and vpu are important for efficient human immunodeficiency virus type 1 replication and CD4+ T-cell depletion in human lymphoid tissue ex vivo. J. Virol. 78 (2004) 12689-12693
51. Salter R.D., Howell D.N., and Cresswell P. Genes regulating HLA class-I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21 (1985) 235-246
52. Sethi A.K., Celentano D.D., Gange S.J., Moore R.D., and Gallant J.E. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37 (2003) 1112-1118
53. Sherman M.P., de Noronha C.M., Eckstein L.A., Hataye J., Mundt P., Williams S.A., Neidleman J.A., Goldsmith M.A., and Greene W.C. Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. J. Virol. 77 (2003) 7582-7589
54. Sherman M.P., de Noronha C.M., Pearce D., and Greene W.C. Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J. Virol. 74 (2000) 8159-8165
55. Strain M.C., Little S.J., Daar E.S., Havlir D.V., Gunthard H.F., Lam R.Y., Daly O.A., Nguyen J., Ignacio C.C., Spina C.A., Richman D.D., and Wong J.K. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191 (2005) 1410-1418
56. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., and Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 (2004) 848-853
57. Sulkowski M.S., Thomas D.L., Chaisson R.E., and Moore R.D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283 (2000) 74-80
58. Sun L., Finnegan C.M., Kish-Catalone T., Blumenthal R., Garzino-Demo P., La Terra Maggiore G.M., Berrone S., Kleinman C., Wu Z., Abdelwahab S., Lu W., and Garzino-Demo A. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J. Virol. 79 (2005) 14318-14329
59. Thotala D., Schafer E.A., Tungaturthi P.K., Majumder B., Janket M.L., Wagner M., Srinivasan A., Watkins S., and Ayyavoo V. Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. Virology 328 (2004) 89-100
60. UNAIDS/WHO Fact Sheet. www.unaids.org.
61. Vanitharani R., Mahalingam S., Rafaeli Y., Singh S.P., Srinivasan A., Weiner D.B., and Ayyavoo V. HIV-1 Vpr transactivates LTR-directed expression through sequences present within -278 to -176 and increases virus replication in vitro. Virology 289 (2001) 334-342
62. Wang L., Mukherjee S., Jia F., Narayan O., and Zhao L.J. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J. Biol. Chem. 270 (1995) 25564-25569
63. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 (2002) 1896-1905
64. Wong J.K., Hezareh M., Gunthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., and Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 (1997) 1291-1295
65. Yap M.W., Nisole S., Lynch C., and Stoye J.P. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 29 (2004) 10786-10791